The Roles of Endogenous D2R Dopamine and µ-opioid Receptors of the Brain in Alcohol use Disorder


Cite item

Full Text

Abstract

:Alcohol use disorder (AUD) affects millions of people worldwide. It is characterized by a strong physiological and psychological craving to consume large amounts of alcohol despite adverse consequences. Alcohol use disorder carries a large health and economic burden on society. Despite its prevalence, AUD is still severely undertreated. The precise molecular mechanisms of how alcohol addiction forms are yet unknown. However, previous studies on animal models show that along with the µ-opioid receptors, the D2R dopamine receptors may also be involved in alcohol craving and reward pathways. Currently, there is a limited number of treatment strategies for alcohol use disorder, which include several medications and therapy. By understanding the limitations of current treatment options and exploring new potential targets, it could be possible to find more effective ways of treating AUD in the future.

About the authors

Kamila Khikhmetova

School of Medicine, Nazarbayev University

Email: info@benthamscience.net

Yuliya Semenova

School of Medicine, Nazarbayev University

Author for correspondence.
Email: info@benthamscience.net

Geir Bjørklund

Department of Research, Council for Nutritional and Environmental Medicine

Author for correspondence.
Email: info@benthamscience.net

References

  1. Sudhinaraset, M.; Wigglesworth, C.; Takeuchi, D.T. Social and cultural contexts of alcohol use: Influences in a social-ecological framework. Alcohol Res., 2016, 38(1), 35-45. PMID: 27159810
  2. Morris, H.; Larsen, J.; Catterall, E.; Moss, A.C.; Dombrowski, S.U. Peer pressure and alcohol consumption in adults living in the UK: A systematic qualitative review. BMC Public Health, 2020, 20(1), 1014. doi: 10.1186/s12889-020-09060-2 PMID: 32631278
  3. Moreno, M.A.; Whitehill, J.M. Influence of social media on alcohol use in adolescents and young adults. Alcohol Res., 2014, 36(1), 91-100. PMID: 26259003
  4. Tucker, J.S.; Rodriguez, A.; Green, H.D., Jr; Pollard, M.S. Trajectories of alcohol use and problems during the COVID-19 pandemic: The role of social stressors and drinking motives for men and women. Drug Alcohol Depend., 2022, 232, 109285. doi: 10.1016/j.drugalcdep.2022.109285 PMID: 35033955
  5. Rehm, J. The risks associated with alcohol use and alcoholism. Alcohol Res. Health, 2011, 34(2), 135-143. PMID: 22330211
  6. Singh, S.K.; Ramanan, V.V. A study on alcohol use and its related health and social problems in rural Puducherry, India. J. Family Med. Prim. Care, 2016, 5(4), 804-808. doi: 10.4103/2249-4863.201175 PMID: 28348995
  7. Kassym, L.; Kussainova, A.; Semenova, Y.; Kussainov, A.; Marapov, D.; Zhanaspayev, M.; Urazalina, Z.; Akhmetova, A.; Tokanov, M.; Smail, Y.; Bjørklund, G. Worldwide prevalence of alcohol use in non-fatally injured motor vehicle drivers: A systematic review and meta-analysis. Healthcare, 2023, 11(5), 758. doi: 10.3390/healthcare11050758 PMID: 36900763
  8. Rumgay, H.; Murphy, N.; Ferrari, P.; Soerjomataram, I. Alcohol and cancer: Epidemiology and biological mechanisms. Nutrients, 2021, 13(9), 3173. doi: 10.3390/nu13093173 PMID: 34579050
  9. Xie, X.; Feng, K.; Wang, J.; Zhang, M.; Hong, J.; Zhang, H. Comprehensive visual electrophysiological measurements discover crucial changes caused by alcohol addiction in humans: Clinical values in early prevention of alcoholic vision decline. Front. Neural Circuits, 2022, 16, 912883. doi: 10.3389/fncir.2022.912883 PMID: 36034334
  10. Sutherland, G.T.; Sheedy, D.; Kril, J.J. Neuropathology of alcoholism. Handb. Clin. Neurol., 2014, 125, 603-615. doi: 10.1016/B978-0-444-62619-6.00035-5 PMID: 25307599
  11. Banerjee, N. Neurotransmitters in alcoholism: A review of neurobiological and genetic studies. Indian J. Hum. Genet., 2014, 20(1), 20-31. doi: 10.4103/0971-6866.132750 PMID: 24959010
  12. Wackernah, R.C.; Minnick, M.J.; Clapp, P. Alcohol use disorder: Pathophysiology, effects, and pharmacologic options for treatment. Subst. Abuse Rehabil., 2014, 5, 1-12. PMID: 24648792
  13. Hussain, R.; Zubair, H.; Pursell, S.; Shahab, M. Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches. Brain Sci., 2018, 8(9), 177. doi: 10.3390/brainsci8090177 PMID: 30223579
  14. Martinez, J.A.; Steinley, D.; Sher, K.J. Deliberate induction of alcohol tolerance: Empirical introduction to a novel health risk. Addiction, 2010, 105(10), 1767-1770. doi: 10.1111/j.1360-0443.2010.03042.x PMID: 20840199
  15. Haass-Koffler, C.L.; Perciballi, R. Alcohol tolerance in human laboratory studies for development of medications to treat alcohol use disorder. Alcohol Alcohol., 2020, 55(2), 129-135. doi: 10.1093/alcalc/agz103 PMID: 31950152
  16. Cederbaum, A.I. Alcohol metabolism. Clin. Liver Dis., 2012, 16(4), 667-685. doi: 10.1016/j.cld.2012.08.002 PMID: 23101976
  17. Yang, W.; Singla, R.; Maheshwari, O.; Fontaine, C.J.; Gil-Mohapel, J. Alcohol use disorder: Neurobiology and therapeutics. Biomedicines, 2022, 10(5), 1192. doi: 10.3390/biomedicines10051192 PMID: 35625928
  18. Diagnostic and statistical manual of mental disorders; American Psychiatric Association, 2013.
  19. Ritchie, H.; Roser, M. Alcohol Consumption 2018. Available from: https://ourworldindata.org/alcohol-consumption
  20. McCrady, B.S.; Flanagan, J.C. The role of the family in alcohol use disorder recovery for adults. Alcohol Res, 2021, 41(1), 06.
  21. Huebner, R.B.; Kantor, L.W. Advances in alcoholism treatment. Alcohol Res. Health, 2011, 33(4), 295-299. PMID: 23580014
  22. Carroll, K.M.; Kiluk, B.D. Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again. Psychol. Addict. Behav., 2017, 31(8), 847-861. doi: 10.1037/adb0000311 PMID: 28857574
  23. Flanagan, J.C.; Jones, J.L.; Jarnecke, A.M.; Back, S.E. Behavioral treatments for alcohol use disorder and post-traumatic stress disorder. Alcohol Res., 2018, 39(2), 181-192. PMID: 31198657
  24. Winslow, B.T.; Onysko, M.; Hebert, M. Medications for alcohol use disorder. Am. Fam. Physician, 2016, 93(6), 457-465. PMID: 26977830
  25. Mason, B.J.; Heyser, C.J. Alcohol use disorder: The role of medication in recovery. Alcohol Res, 2021, 41(1), 07.
  26. Anton, R.F.; O’Malley, S.S.; Ciraulo, D.A.; Cisler, R.A.; Couper, D.; Donovan, D.M.; Gastfriend, D.R.; Hosking, J.D.; Johnson, B.A.; LoCastro, J.S.; Longabaugh, R.; Mason, B.J.; Mattson, M.E.; Miller, W.R.; Pettinati, H.M.; Randall, C.L.; Swift, R.; Weiss, R.D.; Williams, L.D.; Zweben, A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA, 2006, 295(17), 2003-2017. doi: 10.1001/jama.295.17.2003 PMID: 16670409
  27. Wang, S. Historical review: Opiate addiction and opioid receptors. Cell Transplant., 2019, 28(3), 233-238. doi: 10.1177/0963689718811060 PMID: 30419763
  28. Pathan, H.; Williams, J. Basic opioid pharmacology: An update. Br. J. Pain, 2012, 6(1), 11-16. doi: 10.1177/2049463712438493 PMID: 26516461
  29. Le Merrer, J.; Becker, J.A.J.; Befort, K.; Kieffer, B.L. Reward processing by the opioid system in the brain. Physiol. Rev., 2009, 89(4), 1379-1412. doi: 10.1152/physrev.00005.2009 PMID: 19789384
  30. Dhaliwal, A.; Gupta, M. In StatPearls; StatPearls Publishing Copyright © 2022; StatPearls Publishing LLC: Treasure Island, FL, 2022.
  31. Koehl, A.; Hu, H.; Maeda, S.; Zhang, Y.; Qu, Q.; Paggi, J.M.; Latorraca, N.R.; Hilger, D.; Dawson, R.; Matile, H.; Schertler, G.F.X.; Granier, S.; Weis, W.I.; Dror, R.O.; Manglik, A.; Skiniotis, G.; Kobilka, B.K. Structure of the µ-opioid receptor–Gi protein complex. Nature, 2018, 558(7711), 547-552. doi: 10.1038/s41586-018-0219-7 PMID: 29899455
  32. Pasternak, G.W. Opioids and their receptors: Are we there yet? Neuropharmacology, 2014, 76(Pt B), 198-203.
  33. Crist, R.C.; Berrettini, W.H. Pharmacogenetics of OPRM1. Pharmacol. Biochem. Behav., 2014, 123, 25-33. doi: 10.1016/j.pbb.2013.10.018 PMID: 24201053
  34. Feng, Y.; He, X.; Yang, Y.; Chao, D.; Lazarus, L.H.; Xia, Y. Current research on opioid receptor function. Curr. Drug Targets, 2012, 13(2), 230-246. doi: 10.2174/138945012799201612 PMID: 22204322
  35. Bello, M. Molecular basis of inhibitory mechanism of naltrexone and its metabolites through structural and energetic analyses. Molecules, 2022, 27(15), 4919. doi: 10.3390/molecules27154919 PMID: 35956868
  36. Siuda, E.R.; Copits, B.A.; Schmidt, M.J.; Baird, M.A.; Al-Hasani, R.; Planer, W.J.; Funderburk, S.C.; McCall, J.G.; Gereau, R.W., IV; Bruchas, M.R. Spatiotemporal control of opioid signaling and behavior. Neuron, 2015, 86(4), 923-935. doi: 10.1016/j.neuron.2015.03.066 PMID: 25937173
  37. Bera, I.; Laskar, A.; Ghoshal, N. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: A comparative study. J. Mol. Model., 2011, 17(5), 1207-1221. doi: 10.1007/s00894-010-0803-8 PMID: 20661609
  38. Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Mathiesen, J.M.; Sunahara, R.K.; Pardo, L.; Weis, W.I.; Kobilka, B.K.; Granier, S. Crystal structure of the µ-opioid receptor bound to a morphinan antagonist. Nature, 2012, 485(7398), 321-326. doi: 10.1038/nature10954 PMID: 22437502
  39. Arimont, M.; Hoffmann, C.; de Graaf, C.; Leurs, R. Chemokine receptor crystal structures: What Can be learned from them? Mol. Pharmacol., 2019, 96(6), 765-777. doi: 10.1124/mol.119.117168 PMID: 31266800
  40. Ben Hamida, S.; Boulos, L.J.; McNicholas, M.; Charbogne, P.; Kieffer, B.L. Mu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking. Addict. Biol., 2019, 24(1), 28-39. doi: 10.1111/adb.12576 PMID: 29094432
  41. Hermann, D.; Hirth, N.; Reimold, M.; Batra, A.; Smolka, M.N.; Hoffmann, S.; Kiefer, F.; Noori, H.R.; Sommer, W.H.; Reischl, G.; la Fougère, C.; Mann, K.; Spanagel, R.; Hansson, A.C. Low µ-opioid receptor status in alcohol dependence identified by combined positron emission tomography and post-mortem brain analysis. Neuropsychopharmacology, 2017, 42(3), 606-614. doi: 10.1038/npp.2016.145 PMID: 27510425
  42. Li, L; Chen, J; Li, YQ The downregulation of opioid receptors and neuropathic pain. Int J Mol Sci., 2023, 24(6), 5981. doi: 10.3390/ijms24065981
  43. Ohgi, Y. Alcohol dependence and opioid receptor —Pharmacological profile of nalmefene—. Nippon Yakurigaku Zasshi, 2020, 155(3), 145-148. doi: 10.1254/fpj.19139 PMID: 32378631
  44. Mitchell, J.M.; O’Neil, J.P.; Janabi, M.; Marks, S.M.; Jagust, W.J.; Fields, H.L. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci. Transl. Med., 2012, 4(116), 116ra6. doi: 10.1126/scitranslmed.3002902 PMID: 22238334
  45. Singh, D.; Saadabadi, A. In StatPearls; StatPearls Publishing Copyright © 2022; StatPearls Publishing LLC: Treasure Island, FL, 2022.
  46. Srivastava, A.B.; Gold, M.S. Naltrexone: A history and future directions. Cerebrum, 2018, 2018
  47. Malone, M.; McDonald, R.; Vittitow, A.; Chen, J.; Obi, R.; Schatz, D.; Tofighi, B.; Garment, A.; Kermack, A.; Goldfeld, K.; Gold, H.; Laska, E.; Rotrosen, J.; Lee, J.D. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). Contemp. Clin. Trials, 2019, 81, 102-109. doi: 10.1016/j.cct.2019.04.006 PMID: 30986535
  48. Heilig, M.; Goldman, D.; Berrettini, W.; O’Brien, C.P. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat. Rev. Neurosci., 2011, 12(11), 670-684. doi: 10.1038/nrn3110 PMID: 22011682
  49. Mikus, N.; Korb, S.; Massaccesi, C.; Gausterer, C.; Graf, I.; Willeit, M.; Eisenegger, C.; Lamm, C.; Silani, G.; Mathys, C. Effects of dopamine D2/3 and opioid receptor antagonism on the trade-off between model-based and model-free behaviour in healthy volunteers. eLife, 2022, 11, e79661. doi: 10.7554/eLife.79661 PMID: 36468832
  50. Dolan, R.J.; Dayan, P. Goals and habits in the brain. Neuron, 2013, 80(2), 312-325. doi: 10.1016/j.neuron.2013.09.007 PMID: 24139036
  51. Juárez Olguín, H.; Calderón Guzmán, D.; Hernández García, E.; Barragán Mejía, G. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid. Med. Cell. Longev., 2016, 2016, 1-13. doi: 10.1155/2016/9730467 PMID: 26770661
  52. Franco, R.; Reyes-Resina, I.; Navarro, G. Dopamine in health and disease: Much more than a neurotransmitter. Biomedicines, 2021, 9(2), 109. doi: 10.3390/biomedicines9020109 PMID: 33499192
  53. Baik, J.H. Dopamine signaling in reward-related behaviors. Front. Neural Circuits, 2013, 7, 152. doi: 10.3389/fncir.2013.00152 PMID: 24130517
  54. Yang, S.; Boudier-Revéret, M.; Choo, Y.J.; Chang, M.C. Association between chronic pain and alterations in the mesolimbic dopaminergic system. Brain Sci., 2020, 10(10), 701. doi: 10.3390/brainsci10100701 PMID: 33023226
  55. Taylor, A.M.W.; Becker, S.; Schweinhardt, P.; Cahill, C. Mesolimbic dopamine signaling in acute and chronic pain. Pain, 2016, 157(6), 1194-1198. doi: 10.1097/j.pain.0000000000000494 PMID: 26797678
  56. Mishra, A.; Singh, S.; Shukla, S. Physiological and functional basis of dopamine receptors and their role in neurogenesis: Possible implication for Parkinson’s disease. J. Exp. Neurosci., 2018, 12 doi: 10.1177/1179069518779829 PMID: 29899667
  57. Prasad, P.; Ambekar, A.; Vaswani, M. Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: A preliminary study. BMC Med. Genet., 2010, 11(1), 24. doi: 10.1186/1471-2350-11-24 PMID: 20146828
  58. Ma, H.; Zhu, G. The dopamine system and alcohol dependence. Shanghai Jingshen Yixue, 2014, 26(2), 61-68. PMID: 25092951
  59. Feltmann, K.; Borroto-Escuela, D.O.; Rüegg, J.; Pinton, L.; de Oliveira Sergio, T.; Narváez, M.; Jimenez-Beristain, A.; Ekström, T.J.; Fuxe, K.; Steensland, P. Effects of long-term alcohol drinking on the dopamine d2 receptor: Gene expression and heteroreceptor complexes in the striatum in rats. Alcohol. Clin. Exp. Res., 2018, 42(2), 338-351. doi: 10.1111/acer.13568 PMID: 29205397
  60. Bocarsly, M.E.; da Silva e Silva, D.; Kolb, V.; Luderman, K.D.; Shashikiran, S.; Rubinstein, M.; Sibley, D.R.; Dobbs, L.K.; Alvarez, V.A. A mechanism linking two known vulnerability factors for alcohol abuse: Heightened alcohol stimulation and low striatal dopamine D2 receptors. Cell Rep., 2019, 29(5), 1147-1163.e5. doi: 10.1016/j.celrep.2019.09.059 PMID: 31665630
  61. Kamp, F.; Proebstl, L.; Penzel, N.; Adorjan, K.; Ilankovic, A.; Pogarell, O.; Koller, G.; Soyka, M.; Falkai, P.; Koutsouleris, N.; Kambeitz, J. Effects of sedative drug use on the dopamine system: A systematic review and meta-analysis of in vivo neuroimaging studies. Neuropsychopharmacology, 2019, 44(4), 660-667. doi: 10.1038/s41386-018-0191-9 PMID: 30188512
  62. Gleich, T.; Spitta, G.; Butler, O.; Zacharias, K.; Aydin, S.; Sebold, M.; Garbusow, M.; Rapp, M.; Schubert, F.; Buchert, R.; Heinz, A.; Gallinat, J. Dopamine D2/3 receptor availability in alcohol use disorder and individuals at high risk: Towards a dimensional approach. Addict. Biol., 2021, 26(2), e12915. doi: 10.1111/adb.12915 PMID: 32500613
  63. Missale, C. Nerve growth factor, D2 receptor isoforms, and pituitary tumors. Endocrine, 2012, 42(3), 466-467. doi: 10.1007/s12020-012-9756-2 PMID: 22833430
  64. Salinas, A.G.; Mateo, Y.; Carlson, V.C.C.; Stinnett, G.S.; Luo, G.; Seasholtz, A.F.; Grant, K.A.; Lovinger, D.M. Long-term alcohol consumption alters dorsal striatal dopamine release and regulation by D2 dopamine receptors in rhesus macaques. Neuropsychopharmacology, 2021, 46(8), 1432-1441. doi: 10.1038/s41386-020-00938-8 PMID: 33452430
  65. Tice, A.L.; Laudato, J.A.; Rossetti, M.L.; Wolff, C.A.; Esser, K.A.; Lee, C.; Lang, C.H.; Vied, C.; Gordon, B.S.; Steiner, J.L. Binge alcohol disrupts skeletal muscle core molecular clock independent of glucocorticoids. Am. J. Physiol. Endocrinol. Metab., 2021, 321(5), E606-E620. doi: 10.1152/ajpendo.00187.2021 PMID: 34541876
  66. Sharma, R.; Parikh, M.; Mishra, V.; Sahota, P.; Thakkar, M. Activation of dopamine D2 receptors in the medial shell region of the nucleus accumbens increases Per1 expression to enhance alcohol consumption. Addict. Biol., 2022, 27(2), e13133. doi: 10.1111/adb.13133 PMID: 35032086
  67. Ramchandani, V.A.; Umhau, J.; Pavon, F.J.; Ruiz-Velasco, V.; Margas, W.; Sun, H.; Damadzic, R.; Eskay, R.; Schoor, M.; Thorsell, A.; Schwandt, M.L.; Sommer, W.H.; George, D.T.; Parsons, L.H.; Herscovitch, P.; Hommer, D.; Heilig, M. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry, 2011, 16(8), 809-817. doi: 10.1038/mp.2010.56 PMID: 20479755
  68. Hillemacher, T.; Rhein, M.; Burkert, A.; Heberlein, A.; Wilhelm, J.; Glahn, A.; Muschler, M.A.N.; Kahl, K.G.; Kornhuber, J.; Bleich, S.; Frieling, H. DNA-methylation of the dopamin receptor 2 gene is altered during alcohol withdrawal. Eur. Neuropsychopharmacol., 2019, 29(11), 1250-1257. doi: 10.1016/j.euroneuro.2019.09.002 PMID: 31530416
  69. Swift, R.M.; Aston, E.R. Pharmacotherapy for alcohol use disorder: Current and emerging therapies. Harv. Rev. Psychiatry, 2015, 23(2), 122-133. doi: 10.1097/HRP.0000000000000079 PMID: 25747925
  70. Kelly, J.F.; Humphreys, K.; Ferri, M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst. Rev., 2020, 3(3), CD012880. PMID: 32159228
  71. Wnuk, M. The beneficial role of involvement in alcoholics anonymous for existential and subjective well-being of alcohol-dependent individuals? the model verification. Int. J. Environ. Res. Public Health, 2022, 19(9), 5173. doi: 10.3390/ijerph19095173 PMID: 35564567
  72. Srivastava, A.B.; Sanchez-Peña, J.; Levin, F.R.; Mariani, J.J.; Patel, G.H.; Naqvi, N.H. Drinking reduction during cognitive behavioral therapy for alcohol use disorder is associated with a reduction in anterior insula-bed nucleus of the stria terminalis resting-state functional connectivity. Alcohol. Clin. Exp. Res., 2021, 45(8), 1596-1606. doi: 10.1111/acer.14661 PMID: 34342012
  73. Cornelius, J.R.; Douaihy, A.B.; Kirisci, L.; Daley, D.C. Longer-term effectiveness of cbt in treatment of comorbid aud/mdd adolescents. Int. J. Med. Biol. Front., 2013, 19(2) PMID: 25339844
  74. Witkiewitz, K.; Litten, R.Z.; Leggio, L. Advances in the science and treatment of alcohol use disorder. Sci. Adv., 2019, 5(9), eaax4043. doi: 10.1126/sciadv.aax4043 PMID: 31579824
  75. Wilson, A.D.; Roos, C.R.; Robinson, C.S.; Stein, E.R.; Manuel, J.A.; Enkema, M.C.; Bowen, S.; Witkiewitz, K. Mindfulness-based interventions for addictive behaviors: Implementation issues on the road ahead. Psychol. Addict. Behav., 2017, 31(8), 888-896. doi: 10.1037/adb0000319 PMID: 29072477
  76. Korecki, J.R.; Schwebel, F.J.; Votaw, V.R.; Witkiewitz, K. Mindfulness-based programs for substance use disorders: A systematic review of manualized treatments. Subst. Abuse Treat. Prev. Policy, 2020, 15(1), 51. doi: 10.1186/s13011-020-00293-3 PMID: 32727559
  77. Kranzler, H.R.; Soyka, M. Diagnosis and pharmacotherapy of alcohol use disorder. JAMA, 2018, 320(8), 815-824. doi: 10.1001/jama.2018.11406 PMID: 30167705
  78. Brünen, S.; Bekier, N.K.; Hiemke, C.; Korf, F.; Wiedemann, K.; Jahn, H.; Kiefer, F. Therapeutic drug monitoring of naltrexone and 6β-naltrexol during anti-craving treatment in alcohol dependence: Reference ranges. Alcohol Alcohol., 2019, 54(1), 51-55. doi: 10.1093/alcalc/agy067 PMID: 30260366
  79. Rösner, S.; Hackl-Herrwerth, A.; Leucht, S.; Lehert, P.; Vecchi, S.; Soyka, M. Acamprosate for alcohol dependence. Cochrane Database Syst. Rev., 2010, (9), CD004332. PMID: 20824837
  80. Kalk, N.J.; Lingford-Hughes, A.R. The clinical pharmacology of acamprosate. Br. J. Clin. Pharmacol., 2014, 77(2), 315-323. doi: 10.1111/bcp.12070 PMID: 23278595
  81. Carpenter, J.E.; LaPrad, D.; Dayo, Y.; DeGrote, S.; Williamson, K. An overview of pharmacotherapy options for alcohol use disorder. Fed. Pract., 2018, 35(10), 48-58. PMID: 30766325
  82. Pedersen, B.; Askgaard, G.; Jørgensen, C.; Oppedal, K.; Tønnesen, H. In Cochrane Database Syst Rev; Copyright © 2018 The Cochrane Collaboration; John Wiley & Sons, Ltd., 2018, Vol. 2018, .
  83. Heikkinen, M.; Taipale, H.; Tanskanen, A.; Mittendorfer-Rutz, E.; Lähteenvuo, M.; Tiihonen, J. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients. Addiction, 2021, 116(8), 1990-1998. doi: 10.1111/add.15384 PMID: 33394527
  84. Edelman, E.J.; Moore, B.A.; Holt, S.R.; Hansen, N.; Kyriakides, T.C.; Virata, M.; Brown, S.T.; Justice, A.C.; Bryant, K.J.; Fiellin, D.A.; Fiellin, L.E. Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: A randomized-controlled trial. AIDS Behav., 2019, 23(1), 211-221. doi: 10.1007/s10461-018-2241-z PMID: 30073637
  85. Santos, G.M.; Ikeda, J.; Coffin, P.; Walker, J.; Matheson, T.; Ali, A.; McLaughlin, M.; Jain, J.; Arenander, J.; Vittinghoff, E.; Batki, S. Targeted oral naltrexone for mild to moderate alcohol use disorder among sexual and gender minority men: A randomized trial. Am. J. Psychiatry, 2022, 179(12), 915-926. doi: 10.1176/appi.ajp.20220335 PMID: 36285404
  86. Higuchi, S. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: A randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study). J. Clin. Psychiatry, 2015, 76(2), 181-188. doi: 10.4088/JCP.13m08940 PMID: 25742205
  87. Maisel, N.C.; Blodgett, J.C.; Wilbourne, P.L.; Humphreys, K.; Finney, J.W. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? Addiction, 2013, 108(2), 275-293. doi: 10.1111/j.1360-0443.2012.04054.x PMID: 23075288
  88. Skinner, M.D.; Lahmek, P.; Pham, H.; Aubin, H.J. Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS One, 2014, 9(2), e87366. doi: 10.1371/journal.pone.0087366 PMID: 24520330
  89. Yoshimura, A.; Kimura, M.; Nakayama, H.; Matsui, T.; Okudaira, F.; Akazawa, S.; Ohkawara, M.; Cho, T.; Kono, Y.; Hashimoto, K.; Kumagai, M.; Sahashi, Y.; Roh, S.; Higuchi, S. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol. Clin. Exp. Res., 2014, 38(2), 572-578. doi: 10.1111/acer.12278 PMID: 24117666
  90. Li, J.; Wang, H.; Li, M.; Shen, Q.; Li, X.; Rong, X.; Peng, Y. Efficacy of pharmacotherapeutics for patients comorbid with alcohol use disorders and depressive symptoms—A bayesian network meta-analysis. CNS Neurosci. Ther., 2020, 26(11), 1185-1197. doi: 10.1111/cns.13437 PMID: 32686291
  91. Mintz, C.M.; Hartz, S.M.; Fisher, S.L.; Ramsey, A.T.; Geng, E.H.; Grucza, R.A.; Bierut, L.J. A cascade of care for alcohol use disorder: Using 2015–2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care. Alcohol. Clin. Exp. Res., 2021, 45(6), 1276-1286. doi: 10.1111/acer.14609 PMID: 33993541
  92. Finn, S.W.; Mejldal, A.; Nielsen, A.S. Public stigma and treatment preferences for alcohol use disorders. BMC Health Serv. Res., 2023, 23(1), 76. doi: 10.1186/s12913-023-09037-y PMID: 36694198
  93. Jones, K.O.; Lopes, S.; Chen, L.; Zhang, L.; Zinzow, H.; Jindal, M.; Mclain, M.; Shi, L. Perceptions about mindfulness-based interventions among individuals recovering from opioid and alcohol use disorders: Findings from focus groups. Complement. Ther. Med., 2019, 46, 131-135. doi: 10.1016/j.ctim.2019.07.013 PMID: 31519269
  94. Burnette, E.M.; Nieto, S.J.; Grodin, E.N.; Meredith, L.R.; Hurley, B.; Miotto, K.; Gillis, A.J.; Ray, L.A. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs, 2022, 82(3), 251-274. doi: 10.1007/s40265-021-01670-3 PMID: 35133639
  95. Yang, L.H.; Wong, L.Y.; Grivel, M.M.; Hasin, D.S. Stigma and substance use disorders. Curr. Opin. Psychiatry, 2017, 30(5), 378-388. doi: 10.1097/YCO.0000000000000351 PMID: 28700360
  96. Park, Y.S.; Park, S.M.; Jun, J.Y.; Kim, S.J. Psychiatry in former socialist countries: Implications for north korean psychiatry. Psychiatry Investig., 2014, 11(4), 363-370. doi: 10.4306/pi.2014.11.4.363 PMID: 25395966
  97. Hammarlund, R.A.; Crapanzano, K.A.; Luce, L.; Mulligan, L.A.; Ward, K.M. Review of the effects of self-stigma and perceived social stigma on the treatment-seeking decisions of individuals with drug- and alcohol-use disorders. Subst. Abuse Rehabil., 2018, 9, 115-136. doi: 10.2147/SAR.S183256 PMID: 30538599
  98. Walker, J.R.; Korte, J.E.; McRae-Clark, A.L.; Hartwell, K.J. Adherence across FDA-approved medications for alcohol use disorder in a veterans administration population. J. Stud. Alcohol Drugs, 2019, 80(5), 572-577. doi: 10.15288/jsad.2019.80.572 PMID: 31603760
  99. Hell, M.E.; Nielsen, A.S. Does patient involvement in treatment planning improve adherence, enrollment and other treatment outcome in alcohol addiction treatment? A systematic review. Addict. Res. Theory, 2020, 28(6), 537-545. doi: 10.1080/16066359.2020.1723083
  100. Ray, L.A.; Bujarski, S.; Grodin, E.; Hartwell, E.; Green, R.; Venegas, A.; Lim, A.C.; Gillis, A.; Miotto, K. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am. J. Drug Alcohol Abuse, 2019, 45(2), 124-140. doi: 10.1080/00952990.2018.1528265 PMID: 30373394
  101. van Amsterdam, J.; Blanken, P.; Spijkerman, R.; van den Brink, W.; Hendriks, V. The added value of pharmacotherapy to cognitive behavior therapy and vice versa in the treatment of alcohol use disorders: A systematic review. Alcohol Alcohol., 2022, 57(6), agac043. doi: 10.1093/alcalc/agac043 PMID: 36085572
  102. Segher, K.; Huys, L.; Desmet, T.; Steen, E.; Chys, S.; Buylaert, W.; De Paepe, P. Recognition of a disulfiram ethanol reaction in the emergency department is not always straightforward. PLoS One, 2020, 15(12), e0243222. doi: 10.1371/journal.pone.0243222 PMID: 33270785
  103. Li, Q.; Okada, Y.; Marczak, E.; Wilson, W.A.; Lazarus, L.H.; Swartzwelder, H.S. The novel micro-opioid receptor antagonist, N-allyl-Dmt(1)endomorphin-2, attenuates the enhancement of GABAergic neurotransmission by ethanol. Alcohol Alcohol., 2008, 44(1), 13-19. doi: 10.1093/alcalc/agn085 PMID: 18971291

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers